CONGRESS 2016

Hepatitis C - Monday, January 11th 2016

  • 08:30 Introduction: Treatment of hepatitis C: Access to eradication ! - Patrick MARCELLIN (France)
  • 08:40 - 09:00 State of the art lecture - Chairman: Tarik ASSELAH (France)
  • The influence of therapy on the burden of hepatitis C - Michael FRIED (USA)
  • 09:00 Why do I treat my patients with mild hepatitis? - Antonio CRAXI (Italy)
  • 09:15 Why don’t I treat my patients with mild hepatitis? - Christophe HEZODE (France)
  • 09:30 Is the benefit to treat patients with cirrhosis proven? - Savino BRUNO (Italy)
  • 09:45 Round table discussion
  • 10:00 - 10:20 Coffee break
  • 10:20 Is it useful to detect resistance associated variants? - Stefan ZEUZEM (Germany)
  • 10:35 Individual optimization of therapy (shorten therapy) - Graham FOSTER (UK)
  • 10:50 Round table discussion
  • 14:30 Patients with chronic Kidney diseases - Stanislas POL (France)
  • 15:15 Round table discussion
  • 15:35 - 16:05 Coffee break
  • 16:05 How to improve the therapeutic strategies? - Tarik ASSELAH (France)
  • 16:20 How to provide the best treat with what is available? - David NELSON (USA)
  • 16:35 Round table discussion
  • 17:25 Round table discussion
  • 19:30 Congress dinner

HEPATITIS B - Tuesday, January 12th 2016

  • 08:40 Clinical relevance of HBV cccDNA - Fabien ZOULIM (France)
  • 09:30 Round table discussion
  • 10:00 - 10:30 Coffee break
  • 11:00 Which pregnant women to treat? - Ji Dong JIA (China)
  • 11:15 Round table discussion
  • 11:45 - 12:15 State of the art lecture - Chairman: Marc BOURLIERE (France)
  • 14:15 - 14:45 State of the art lecture and award - Chairman: Patrick MARCELLIN (France)
  • 14:45 Management of uninfected and infected ascites in cirrhosis - Pere GINES (Spain)
  • 15:15 Treatment of hepatocellular carcinoma: beyond international guidelines - Massimo COLOMBO (Italy)
  • 15:30 Round table discussion
  • 16:20 Closing session